Physician profile
Amber Jackson
NPI 1588360473
$7,197.15
in general payments reported to CMS, 2019-2025
21 companies · $3,363 in 2025
The $3,363 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,739 · 2024: $2,095 · 2025: $3,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,918 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,917.53 |
| Education | $279.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $996.06 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $863.83 | 2023-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $759.81 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $710.74 | 2023-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $447.11 | 2023-2025 | Siliq, Targretin, Duobrii |
| Galderma Laboratories, L.P. | $409.97 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $396.53 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $342.72 | 2023-2025 | |
| Dermavant Sciences, INC. | $334.79 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $325.78 | 2023-2024 | Absorica Ld, Winlevi, Blu-U |
| Incyte Corporation | $254.77 | 2023-2025 | Opzelura, Opzelura |
| Organon LLC | $240.02 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.18 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $190.81 | 2023-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $170.58 | 2024-2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.24 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.13 | 2024 | Sotyktu |
| Amgen INC. | $104.10 | 2024-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $90.96 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $67.51 | 2024-2025 | Nuzyra |
| Tactile Systems Technology INC | $14.51 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.